Anti-Siglec-2/CD22 Antibody (Epratuzumab)
Catalog No.
F1187
Anti-Siglec-2/CD22 Antibody (Epratuzumab)
Featured Products
Epratuzumab (Antibody hLL 2) is an anti-CD22IgG1 Monoclonal antibody. Epratuzumab is also a tumor imaging agent and immunomodulator. Epratuzumab can induceCD22 Phosphorylation. Epratuzumab has been studied in non-Hodgkin lymphoma and some autoimmune diseases.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.58 kDa
Dry ice
205923-57-5
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
Lymphocide, AMG 412, hLL2
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P20273
Human
Unconjugated
Monoclonal
Protein A
IgG4SP
ELISA, FACS, Kinetics, Functional assay, Animal Model
Siglec-2 / CD22
Please avoid freeze-thaw cycles.